BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2015840)

  • 1. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
    May TW; Rambeck B; Nothbaum N
    Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication.
    May T; Rambeck B
    Ther Drug Monit; 1990 Mar; 12(2):124-8. PubMed ID: 2107607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods.
    Kerrick JM; Wolff DL; Graves NM
    Ann Pharmacother; 1995 May; 29(5):470-4. PubMed ID: 7655129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid.
    Haidukewych D; Rodin EA; Zielinski JJ
    Ther Drug Monit; 1989; 11(2):134-9. PubMed ID: 2497562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid-phenytoin interaction.
    Friel PN; Leal KW; Wilensky AJ
    Ther Drug Monit; 1979; 1(2):243-8. PubMed ID: 122160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children.
    Ueshima S; Aiba T; Makita T; Nishihara S; Kitamura Y; Kurosaki Y; Kawasaki H; Sendo T; Ohtsuka Y; Gomita Y
    J Clin Pharm Ther; 2008 Feb; 33(1):31-8. PubMed ID: 18211614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin.
    Miles MV; Snead OC; Thorn MD
    Clin Pharm; 1988 Sep; 7(9):688-93. PubMed ID: 3149223
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum concentrations of valproic acid: influence of dose and comedication.
    May T; Rambeck B
    Ther Drug Monit; 1985; 7(4):387-90. PubMed ID: 3936236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valproate on free plasma phenytoin concentrations.
    Tsanaclis LM; Allen J; Perucca E; Routledge PA; Richens A
    Br J Clin Pharmacol; 1984 Jul; 18(1):17-20. PubMed ID: 6430316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of binding equation method for prediction of unbound serum valproic acid concentration in pediatric patients with epilepsy.
    Kodama Y; Kuranari M; Kodama H; Koike Y; Yasunaga F; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):114-8. PubMed ID: 7757310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent interaction between phenytoin and valproic acid.
    Riva R; Albani F; Contin M; Perucca E; Ambrosetto G; Gobbi G; Santucci M; Procaccianti G; Baruzzi A
    Neurology; 1985 Apr; 35(4):510-5. PubMed ID: 3920548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of total and free phenytoin serum concentrations measured by high-performance liquid chromatography and standard TDx assay: implications for the prediction of free phenytoin serum concentrations.
    May TW; Rambeck B; Jürges U; Blankenhorn V; Jürgens U
    Ther Drug Monit; 1998 Dec; 20(6):619-23. PubMed ID: 9853976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
    Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
    J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
    Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
    Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate.
    de Wolff FA; Peters AC; van Kempen GM
    Neuropediatrics; 1982 Feb; 13(1):10-3. PubMed ID: 6123089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients.
    Garzón P; González-Cornejo S; Román-Maldonado S; Navarro-Ruiz A
    Gen Pharmacol; 1985; 16(4):411-3. PubMed ID: 2412936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.